Biperiden
Biperiden has been studied in 1 paper since 2025: 1 trial in people; 1 in the past year. The newest paper, Dec 25, 2025: “Assessing biomarkers for predicting Alzheimer's disease in TBI patients: A subanalysis of the double‐blinded, phase III randomized clinical trial with biperiden”.
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“While biperiden treatment did not significantly alter biomarker levels across the overall cohort”
Humans: a single group. Cells, worms or flies and mice: nothing yet.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave biperiden to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on GFAP | Randomized trial | 123 peopleBothAcute phase post-TBI | AAIC 2025 abstract, Dec 25, 2025 |
What did studies of biperiden find?
1Studies of biperiden measured one outcome, GFAP.
GFAP
no changein humans1
1 study
GFAP
no changein humans1
Biperiden showed no clear effect on GFAP in humans (acute phase post-TBI).
“While biperiden treatment did not significantly alter biomarker levels across the overall cohort”
Human trialacute phase post-TBIserum
AAIC 2025 abstract
Latest
1 paper in 12 monthsAAIC 2025 Abstract
Assessing biomarkers for predicting Alzheimer's disease in TBI patients: A subanalysis of the double‐blinded, phase III randomized clinical trial with biperiden
Randomized trial in 123 peopleAlzheimer's disease
Journal of Clinical Pharmacology
Biperiden Challenge Model in Healthy Elderly as Proof-of-Pharmacology Tool: A Randomized, Placebo-Controlled Trial
Trial in peopleMechanisms